» Articles » PMID: 35948909

Metabolic Profiles of Regulatory T Cells and Their Adaptations to the Tumor Microenvironment: Implications for Antitumor Immunity

Overview
Journal J Hematol Oncol
Publisher Biomed Central
Specialties Hematology
Oncology
Date 2022 Aug 10
PMID 35948909
Authors
Affiliations
Soon will be listed here.
Abstract

Characterized by the expression of the critical transcription factor forkhead box protein P3, regulatory T (Treg) cells are an essential part of the immune system, with a dual effect on the pathogenesis of autoimmune diseases and cancer. Targeting Tregs to reestablish the proinflammatory and immunogenic tumor microenvironment (TME) is an increasingly attractive strategy for cancer treatment and has been emphasized in recent years. However, attempts have been significantly hindered by the subsequent autoimmunity after Treg ablation owing to systemic loss of their suppressive capacity. Cellular metabolic reprogramming is acknowledged as a hallmark of cancer, and emerging evidence suggests that elucidating the underlying mechanisms of how intratumoral Tregs acquire metabolic fitness and superior immunosuppression in the TME may contribute to clinical benefits. In this review, we discuss the common and distinct metabolic profiles of Tregs in peripheral tissues and the TME, as well as the differences between Tregs and other conventional T cells in their metabolic preferences. By focusing on the critical roles of different metabolic programs, such as glycolysis, oxidative phosphorylation, fatty acid oxidation, fatty acid synthesis, and amino acid metabolism, as well as their essential regulators in modulating Treg proliferation, migration, and function, we hope to provide new insights into Treg cell-targeted antitumor immunotherapies.

Citing Articles

Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review.

Tom V, Jose A, Mallick S, Sasidharan A, Pawar R, Somayaji Y Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40063239 DOI: 10.1007/s00210-025-03985-4.


Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications.

Xie X, Liu W, Yuan Z, Chen H, Mao W Mol Cancer. 2025; 24(1):71.

PMID: 40057791 PMC: 11889836. DOI: 10.1186/s12943-025-02269-y.


Multi-omics analysis identifies UBA family as potential pan-cancer biomarkers for tumor prognosis and immune microenvironment infiltration.

Wang H, Liu X, Huang H, Tang M, Li J, Huang T Front Immunol. 2025; 16:1510503.

PMID: 40046044 PMC: 11880792. DOI: 10.3389/fimmu.2025.1510503.


Fluoride-Mediated Immune Damage Through Cytokine Network Regulation of Tregs.

Liu B, Zhu S, Zhang Q, Xie F, Wei D, Fu G Toxics. 2025; 13(2).

PMID: 39997909 PMC: 11861542. DOI: 10.3390/toxics13020095.


Global Trends in Research of Amino Acid Metabolism in T Lymphocytes in Recent 15 Years: A Bibliometric Analysis.

Xu J, Yu Y, Li S, Qiu F J Immunol Res. 2025; 2025:3393342.

PMID: 39950085 PMC: 11824865. DOI: 10.1155/jimr/3393342.


References
1.
Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y . Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2019; 80(3):499-509. DOI: 10.1158/0008-5472.CAN-19-1577. View

2.
Lowe M, Boothby I, Clancy S, Ahn R, Liao W, Nguyen D . Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI Insight. 2019; 4(24). PMC: 6975275. DOI: 10.1172/jci.insight.129756. View

3.
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

4.
Yang Z, Guo J, Weng L, Tang W, Jin S, Ma W . Myeloid-derived suppressor cells-new and exciting players in lung cancer. J Hematol Oncol. 2020; 13(1):10. PMC: 6995114. DOI: 10.1186/s13045-020-0843-1. View

5.
Hanna B, Roessner P, Scheffold A, Jebaraj B, Demerdash Y, Ozturk S . PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia. 2018; 33(6):1427-1438. DOI: 10.1038/s41375-018-0318-3. View